Biohaven Secures $600m Financing as It Awaits FDA Prodrug Decision
Baird Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $57
Why BioHaven Stock Is Soaring Today
$BHVN Stock Is up 7% Today. Here's What We See in Our Data.
Sector Update: Health Care Stocks Mixed Premarket Monday
Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Baird Maintains Outperform on Biohaven, Lowers Price Target to $57
Biohaven Analyst Ratings
Express News | Biohaven Ltd - Oberland Capital to Receive Milestone and Royalty Payments on Net Sales of Troriluzole
Express News | Biohaven Announces Investment up to $600 Million by Oberland Capital
Press Release: Biohaven Announces Investment up to $600 Million by Oberland Capital
William Blair Initiates Biohaven(BHVN.US) With Buy Rating
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $61
Why Biohaven Stock Plummeted by More Than 15% Today
Sector Update: Health Care Stocks Advance in Afternoon Trading
Biohaven Share Price Undervaluing Pipeline Potential, Says RBC Capital
Biohaven Withdraws Dazluma EU Marketing Application; Shares Fall
Biohaven Down 12% to $20.60 After Pulling European Application
Biohaven Withdraws Initial Marketing Authorization Application For Dazluma-European Medical Agency
Biohaven Withdraws Troriluzole Marketing Application in Europe